The most common allergic condition in the US, allergic rhinitis (AR) affects nearly 40 million people. A chronic condition that negatively impacts productivity and quality of life, AR remains largely undertreated. For some sufferers, comorbidities such as asthma, sinusitis, otitis media, sleep disturbances, and nasal polyps make treatment all the more imperative. While current therapies have proven only modestly successful, emerging therapies offer the promise of more effective management.
Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Healthcare Professional will provide primary care clinicians with up-to-date, evidence-based information on the pathophysiology, diagnosis, and management of patients with allergic rhinitis.
Learning Objectives
After completing this activity, the participant will be able to:
- Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
- Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Release date: February 23, 2009
Expiration date: February 23, 2010
Medium: Podcast
Acknowledgement of Commercial Support:
This activity was developed from the live Best Practices in Primary Care™ program held in Philadelphia, Pennsylvania on April 26, 2008 which was funded by sanofi-aventis.
Method of Participation:
To receive CME credit for this activity, you need to listen to the program. Upon finishing the podcast, complete the post-test and evaluation, and fill out all required personal information. To receive your CME certificate you will need to pass the post-test with 70% accuracy or better.
Post-test and Evaluation:
After completing this activity, click on the Post-test button at the end of the program. If you receive less than 70% on the post-test, you will be returned to the beginning of the activity to review the presentation again. Upon successful completion of the post-test, you will be asked to fill out a program evaluation form and prompted to print your CME certificate.
Statement of Disclosure and Independence:
It is the policy of Primary Care Network, Inc. to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, Primary Care Network has Conflict of Interest and Disclosure Policies that are designed to ensure that Primary Care Network sponsored educational activities are fair balanced, independent, evidence-based and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a Primary Care Network sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations at this Primary Care Education program are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.
Planning Committee and Disclosures
Michael S. Blaiss, MD
Clinical Professor of Pediatrics and Medicine
Division of Clinical Immunology/Allergy
University of Tennessee Health Science Center
Memphis, TN
Dr. Blaiss is a member of the speaker’s bureau for Alcon, Inc., AstraZenca, DEY, L.P., Genentech, Inc., GlaxoSmithKline, Merck & Co., Inc., sanofi-aventis US, and Schering-Plough Corporation. He serves on the advisory boards for Alcon, AstraZeneca, Genentech, GlaxoSmithKline, Merck, sanofi-aventis, and Schering-Plough. Dr. Blaiss is a consultant to Alcon, AstraZeneca, GlaxoSmithKline, Merck, sanofi-aventis, and Schering-Plough, and receives grant support from GlaxoSmithKline.
Anthony Montanaro, MD
Professor of Medicine
Chief, Division of Allergy and Clinical Immunology
Oregon Health & Sciences University
Portland, OR
Dr. Montanaro is a member of the speaker’s bureau for AstraZeneca, GlaxoSmithKline, Merck & Co., Inc., sanofi-aventis U.S., and Schering-Plough Corporation.
Warren Beckman
Senior Vice President
Director, CME Planning and Development
Network for Continuing Medical Education
Secaucus, NJ
Mr. Beckman has nothing to disclose.
Devera Pine
Senior Managing Editor
Network for Continuing Medical Education
Secaucus, NJ
Ms. Pine has nothing to disclose.
Nina Romanoff
Medical Writer
Croton on Hudson, NY
Ms. Romanoff has nothing to disclose.
Faculty and Disclosures
Myron J. Zitt, MD
Clinical Associate Professor of Medicine
State University of New York at Stony Brook
Stony Brook, NY
Dr. Zitt is a member of the speaker’s bureau for Aerocrine AB, Alcon, Inc., AstraZeneca, Genentech, Inc., Merck & Co., Inc., Novartis Pharmaceuticals, sanofi-aventis US, Schering-Plough Corporation, Verus Pharmaceuticals, and UCB Pharma. He serves on the advisory boards for Aerocrine, Alcon, Schering-Plough, and Verus and is a consultant to Aerocrine and Schering Plough.
Ketan K. Sheth, MD, MBA
Private Practice
Lafayette Allergy and Asthma Clinic
Adjunct Associate Professor of Clinical Pharmacy
Purdue University
Clinical Assistant Professor of Pediatrics
Indiana University School of Medicine
Lafayette, IN
Dr. Sheth is a member of the speaker’s bureau for AstraZeneca, GlaxoSmithKline, Pfizer, Inc., sanofi-aventis US, and Schering-Plough Corporation. He serves on the advisory board for GlaxoSmithKline and is a consultant to AstraZeneca and GlaxoSmithKline.
Review Committee Disclosure
In accordance with our policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Unlabeled Use Declaration:
During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
 Listen to Podcast
When finished, click here to take the Post-test
Take the post-test to receive your CME certificate
|
